Lexicon Pharmaceuticals
LXRX
1.73
-0.04
-1.99%
Lexicon Pharmaceuticals
US · LXRX
#3430 by market cap
1.73
-0.04
-1.99%
Live - 5344 symbols - heartbeat 332s ago
· 2026-10-08 09:59
Pre-market
1.75
-0.57%
After-hours
1.76
0.00%
Overnight
1.78
+1.14%
- Market cap
- 767.55M
- P/E (TTM)i
- -10.78
- P/Bi
- 4.40
- EPSi
- -0.14
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on LXRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.1 percentage points.
Institutional ownership
- Held by institutions
- 83.73% +0.12pp
- Institutions
- 169 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund50.55%
Mutual Fund23.82%
Hedge Fund8.20%
Individual/Insider1.46%
Private Company0.49%
Public Company0.40%
Insurance Company0.12%
Government Pension Fund0.11%
Other14.83%
Top holders as of 2026-06-30
Artal Group S.A.
49.32% · 219.46M sh
FMR
11.64% · 51.78M sh
Sessa Capital IM, L.P.
4.26% · 18.96M sh
BlackRock
3.90% · 17.35M sh
Vanguard Capital Management, LLC
2.59% · 11.54M sh
Point72 Asset Management, L.P.
1.85% · 8.25M sh
Geode Capital Management, LLC
1.40% · 6.24M sh
The Invus Group, LLC
1.23% · 5.45M sh
State Street Global Advisors
1.11% · 4.92M sh
Vanguard Portfolio Management, LLC
0.53% · 2.36M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 42 buys · 8 sells
| Name | Role | Stake |
|---|---|---|
| Artal Group S.A. | -- | 49.32% |
| Raymond Debbane | Independent Chairperson | 0.45% |
| Lonnel Coats | Chief Executive Officer | 0.18% |
| Brian Crum | Senior Vice President | 0.10% |
| Philippe Amouyal | Independent Director | 0.08% |
| Alan Main | Executive Vice President of Innovation & Chemical Sciences | 0.08% |
| Craig Granowitz | Senior VP & Chief Medical Officer | 0.07% |
| Jeffrey Wade | President | 0.07% |
| Michael Exton | Chief Executive Officer | 0.07% |
| Christopher Sobecki | Independent Director | 0.07% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-02 | Raymond Debbane | Independent Chairperson | Derivative Exercise and Retained | +89,312 | -- |
| 2026-06-02 | Samuel Barker | Independent Director | Derivative Exercise and Retained | +89,312 | -- |
| 2026-06-02 | Philippe Amouyal | Independent Director | Derivative Exercise and Retained | +89,312 | -- |
| 2026-06-02 | Christopher Sobecki | Independent Director | Derivative Exercise and Retained | +89,312 | -- |
| 2026-06-02 | Judith Swain | Independent Director | Derivative Exercise and Retained | +89,312 | -- |
| 2026-06-02 | Diane Sullivan | Director | Derivative Exercise and Retained | +89,312 | -- |
| 2026-06-02 | Ivan H. Cheung | Director | Derivative Exercise and Retained | +89,312 | -- |
| 2026-04-30 | Raymond Debbane | Independent Chairperson | Other Derivative Acquisition | +35,714 | -- |
| 2026-04-30 | Raymond Debbane | Independent Chairperson | Other Derivative Acquisition | +43,478 | $1.61 |
| 2026-04-30 | Samuel Barker | Independent Director | Other Derivative Acquisition | +35,714 | -- |
| 2026-04-30 | Samuel Barker | Independent Director | Other Derivative Acquisition | +43,478 | $1.61 |
| 2026-04-30 | Philippe Amouyal | Independent Director | Other Derivative Acquisition | +35,714 | -- |
| 2026-04-30 | Philippe Amouyal | Independent Director | Other Derivative Acquisition | +43,478 | $1.61 |
| 2026-04-30 | Christopher Sobecki | Independent Director | Other Derivative Acquisition | +35,714 | -- |
| 2026-04-30 | Christopher Sobecki | Independent Director | Other Derivative Acquisition | +43,478 | $1.61 |
| 2026-04-30 | Judith Swain | Independent Director | Other Derivative Acquisition | +35,714 | -- |
| 2026-04-30 | Judith Swain | Independent Director | Other Derivative Acquisition | +43,478 | $1.61 |
| 2026-04-30 | Diane Sullivan | Director | Other Derivative Acquisition | +35,714 | -- |
| 2026-04-30 | Diane Sullivan | Director | Other Derivative Acquisition | +43,478 | $1.61 |
| 2026-04-30 | Ivan H. Cheung | Director | Other Derivative Acquisition | +35,714 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:59:25 · For reference only, not investment advice and not tailored to your situation.